Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine (Q34650461)

3 August 2017

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine (English)

1 reference

3 August 2017

visceral leishmaniasis

1 reference

1 reference

1 reference

Santos FN

1

1 reference

3 August 2017

Borja-Cabrera GP

2

1 reference

3 August 2017

Miyashiro LM

3

1 reference

3 August 2017

Grechi J

4

1 reference

3 August 2017

Reis AB

5

1 reference

3 August 2017

Moreira MA

6

1 reference

3 August 2017

Martins Filho OA

7

1 reference

3 August 2017

Luvizotto MC

8

1 reference

3 August 2017

Menz I

9

1 reference

3 August 2017

Pessôa LM

10

1 reference

3 August 2017

Gonçalves PR

11

1 reference

3 August 2017

Palatnik M

12

1 reference

3 August 2017

Palatnik-de-Sousa CB

13

1 reference

3 August 2017

language of work or name

English

0 references

publication date

21 June 2007

1 reference

3 August 2017

1 reference

3 August 2017

25

1 reference

3 August 2017

33

1 reference

3 August 2017

6176-6190

1 reference

Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

7 January 2021

12 December 2020

Canine visceral leishmaniasis in Rio de Janeiro, Brazil. Clinical, parasitological, therapeutical and epidemiological findings (1977-1983)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Therapy of murine cutaneous leishmaniasis by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Cytology of cutaneous lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Amplification of kinetoplast DNA as a tool in the detection and diagnosis of Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Susceptibility to visceral leishmaniasis in the domestic dog is associated with MHC class II polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Sand fly saliva enhances Leishmania amazonensis infection by modulating interleukin-10 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

The epidemiology of canine leishmaniasis: transmission rates estimated from a cohort study in Amazonian Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.005

Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice

7 January 2021

1 reference

12 December 2020

The logic of visceral leishmaniasis control

1 reference

12 December 2020

Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML)

1 reference

12 December 2020

Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies.

1 reference

12 December 2020

[Leishmaniasis in dogs. Clinical course of infection, diagnosis and therapy trials following experimental infection of beagles with Leishmania donovani (Calcutta strain)]

1 reference

12 December 2020

1 reference

12 December 2020

Ecology of leishmaniasis in the south of France. 10. Developmental stages and clinical characterization of canine leishmaniasis in relation to epidemiology. (author's transl)

1 reference

12 December 2020

Control of zoonotic visceral leishmaniasis: is it time to change strategies?

1 reference

12 December 2020

10.1016/J.VACCINE.2007.06.005

Identifiers

DOI

1 reference

3 August 2017

0 references

1 reference